Company news
Damora Therapeutics, Inc. (NASDAQ:DMRA) news
Damora Therapeutics, Inc. news releases on 6ix. Latest, Oct 5, 2026: Damora Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(4)
Press releases & updates
Damora Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(4)
October 5, 2026
Damora Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
October 1, 2026
Damora Therapeutics Reports Second Quarter 2026 Financial Results and Recent Corporate Highlights
August 10, 2026
Damora Therapeutics Initiates Phase 1/1b CLARITY-101 Clinical Trial of DMR-001 in Patients with Mutant Calreticulin-Driven Essential Thrombocythemia and Myelofibrosis
August 5, 2026
Damora Announces Redomestication from Delaware to Cayman Islands
July 17, 2026
Damora Therapeutics Reports First Quarter 2026 Financial Results and Recent Corporate Highlights
May 12, 2026
Damora Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(4)
May 4, 2026
Damora Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
March 30, 2026
Damora Therapeutics Appoints Biotechnology Leader Jennifer Jarrett as President and Chief Executive Officer; Adds Two Industry Veterans to Board of Directors
March 23, 2026
Damora Therapeutics Reports Full-Year 2025 Financial Results and Recent Corporate Highlights
March 19, 2026